The U.S. Securities & Exchange Commission has issued a subpoena to BioMet for alleged improprieties concerning its operations in Brazil and Mexico. BioMet has had to pay $22 million in the past for violating government rules and paying kickbacks to employees for promoting its medical devices.
BioMet is facing multiple hip replacement lawsuits concerning its M2a Magnum hip implant. In 2011, a study found that the device was failing in patients at a rate higher than expected, with more than 7% of patients requiring revision surgery within a year. Patients claim that the company released a defective device that caused serious injuries.
Metal-on-metal hip replacements have been subject of serious scrutiny in the medical community after patients complained of multiple complications. BioMet M2a Magnum hip replacement side effects include tissue damage, fretting, corrosion, limited mobility, pain, swelling and toxic levels of metal in the blood stream.